JP2021516991A5 - - Google Patents

Info

Publication number
JP2021516991A5
JP2021516991A5 JP2020568945A JP2020568945A JP2021516991A5 JP 2021516991 A5 JP2021516991 A5 JP 2021516991A5 JP 2020568945 A JP2020568945 A JP 2020568945A JP 2020568945 A JP2020568945 A JP 2020568945A JP 2021516991 A5 JP2021516991 A5 JP 2021516991A5
Authority
JP
Japan
Prior art keywords
seq
protein
amino acid
composition
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020568945A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021516991A (ja
JP7883357B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/020398 external-priority patent/WO2019169328A1/en
Publication of JP2021516991A publication Critical patent/JP2021516991A/ja
Publication of JP2021516991A5 publication Critical patent/JP2021516991A5/ja
Priority to JP2023222587A priority Critical patent/JP2024045151A/ja
Application granted granted Critical
Publication of JP7883357B2 publication Critical patent/JP7883357B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020568945A 2018-03-02 2019-03-01 Cpgアンフィフィル及びその使用 Active JP7883357B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023222587A JP2024045151A (ja) 2018-03-02 2023-12-28 Cpgアンフィフィル及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862637824P 2018-03-02 2018-03-02
US62/637,824 2018-03-02
PCT/US2019/020398 WO2019169328A1 (en) 2018-03-02 2019-03-01 Cpg amphiphiles and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023222587A Division JP2024045151A (ja) 2018-03-02 2023-12-28 Cpgアンフィフィル及びその使用

Publications (3)

Publication Number Publication Date
JP2021516991A JP2021516991A (ja) 2021-07-15
JP2021516991A5 true JP2021516991A5 (cg-RX-API-DMAC7.html) 2022-03-09
JP7883357B2 JP7883357B2 (ja) 2026-07-01

Family

ID=67805576

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020568945A Active JP7883357B2 (ja) 2018-03-02 2019-03-01 Cpgアンフィフィル及びその使用
JP2023222587A Pending JP2024045151A (ja) 2018-03-02 2023-12-28 Cpgアンフィフィル及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023222587A Pending JP2024045151A (ja) 2018-03-02 2023-12-28 Cpgアンフィフィル及びその使用

Country Status (20)

Country Link
US (3) US12247052B2 (cg-RX-API-DMAC7.html)
EP (1) EP3758712B1 (cg-RX-API-DMAC7.html)
JP (2) JP7883357B2 (cg-RX-API-DMAC7.html)
KR (2) KR102837422B1 (cg-RX-API-DMAC7.html)
CN (2) CN112203663A (cg-RX-API-DMAC7.html)
AU (1) AU2019227988B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020017778A2 (cg-RX-API-DMAC7.html)
CA (1) CA3092693A1 (cg-RX-API-DMAC7.html)
DK (1) DK3758712T3 (cg-RX-API-DMAC7.html)
ES (1) ES3035198T3 (cg-RX-API-DMAC7.html)
IL (1) IL277101B2 (cg-RX-API-DMAC7.html)
MA (1) MA52434A (cg-RX-API-DMAC7.html)
MX (1) MX2020009150A (cg-RX-API-DMAC7.html)
MY (1) MY209484A (cg-RX-API-DMAC7.html)
PL (1) PL3758712T3 (cg-RX-API-DMAC7.html)
PT (1) PT3758712T (cg-RX-API-DMAC7.html)
SA (1) SA520420065B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202008432XA (cg-RX-API-DMAC7.html)
UA (1) UA128863C2 (cg-RX-API-DMAC7.html)
WO (1) WO2019169328A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018201090A1 (en) 2017-04-28 2018-11-01 Exicure, Inc. Synthesis of spherical nucleic acids using lipophilic moieties
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)
KR102787353B1 (ko) 2018-03-02 2025-03-26 엘리시오 테라퓨틱스, 인크. 돌연변이 kras 서열 및 지질을 포함하는 화합물 및 이의 용도
CA3183735A1 (en) * 2020-06-26 2021-12-30 Martin P. STEINBUCK Compositions and methods for inducing an immune response against coronavirus
CN116507344A (zh) * 2020-06-26 2023-07-28 伊莱西奥治疗有限公司 用于诱导针对冠状病毒的免疫应答的组合物和方法
WO2023022973A2 (en) * 2021-08-16 2023-02-23 Elicio Therapeutics, Inc. Compositions containing polynucleotide amphiphiles and methods of use thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6168778B1 (en) * 1990-06-11 2001-01-02 Nexstar Pharmaceuticals, Inc. Vascular endothelial growth factor (VEGF) Nucleic Acid Ligand Complexes
AU2001268427B2 (en) 2000-06-16 2007-03-29 Glaxosmithkline Intellectual Property Limited Antibodies that immunospecifically bind to blys
US8771702B2 (en) * 2001-03-26 2014-07-08 The Trustees Of The University Of Pennsylvania Non-hemolytic LLO fusion proteins and methods of utilizing same
JPWO2005001116A1 (ja) * 2003-06-17 2006-08-24 明治乳業株式会社 Toll様レセプター強制発現細胞の利用
US9090673B2 (en) 2003-12-12 2015-07-28 City Of Hope Synthetic conjugate of CpG DNA and T-help/CTL peptide
EP1776105A2 (en) * 2004-07-18 2007-04-25 Coley Pharmaceutical Group, Ltd Methods and compositions for inducing innate immune responses
CN100508764C (zh) 2005-02-05 2009-07-08 田景武 人参保鲜方法
MX2009003398A (es) 2006-09-27 2009-08-12 Coley Pharm Gmbh Analogos de oligonucleotidos cpg que contienen analogos t hidrofobos con actividad inmunoestimuladora mejorada.
EP2155889A4 (en) * 2007-05-25 2010-06-16 Centocor Ortho Biotech Inc TOLL RECEPTOR 3 MODULATORS AND USES THEREOF
WO2010071852A2 (en) 2008-12-19 2010-06-24 University Of Florida Research Foundation, Inc. Oligonucleotide micelles
ES2731343T3 (es) 2009-05-19 2019-11-15 Univ Miami Composiciones, kits y métodos para presentación de antígenos in vitro, evaluación de eficacia de vacunas y evaluación de la inmunotoxicidad de productos biológicos y fármacos
US20120264810A1 (en) * 2009-09-22 2012-10-18 The University Of British Columbia Compositions and methods for enhancing cellular uptake and intracellular delivery of lipid particles
ES2983470T3 (es) 2010-03-19 2024-10-23 Takeda Pharmaceuticals Co Inhibidores del TFPI y métodos de uso
AU2012209274A1 (en) * 2011-01-24 2013-09-12 Anterios, Inc. Nanoparticle compositions, formulations thereof, and uses therefor
BR112013030104A8 (pt) 2011-05-25 2021-09-08 Camurus Ab Pré-formulação, processo para a formação de uma pré-formulação, método de tratamento cosmético, dispositivo de administração preenchido, e, kit
US20150044208A1 (en) 2011-09-23 2015-02-12 Technophage, Investigaçäo E Desenvolvimento Em Biotecnologia, Sa Modified Albumin-Binding Domains and Uses Thereof to Improve Pharmacokinetics
US9694050B2 (en) 2012-10-21 2017-07-04 University Of Rochester THY1 (CD90) as a novel therapy to control adipose tissue accumulation
KR102109188B1 (ko) 2013-04-01 2020-05-11 삼성전자주식회사 양이온성 지질을 포함하는 온도민감성 리포좀 및 그의 용도
AR095882A1 (es) * 2013-04-22 2015-11-18 Hoffmann La Roche Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
KR102100289B1 (ko) * 2013-10-24 2020-04-13 주식회사 다이셀 은 나노 입자 함유 분산액의 제조 방법 및 은 나노 입자 함유 분산액
AU2015314763A1 (en) * 2014-09-11 2017-04-06 Vedantra Pharmaceuticals, Inc. Multilamellar lipid vesicle compositions and methods of use
US10940201B2 (en) * 2015-09-30 2021-03-09 Shionogi & Co., Ltd. Nucleic acid derivative having immunostimulatory activity
KR20190082850A (ko) 2016-11-30 2019-07-10 어드박시스, 인크. 반복되는 암 돌연변이를 표적화하는 면역원 조성물 및 그것의 사용 방법
EP3585428A1 (en) * 2017-02-23 2020-01-01 Alpha-o Peptides AG Self-assembling protein nanoparticles encapsulating immunostimulatory nucleid acids
KR102787353B1 (ko) * 2018-03-02 2025-03-26 엘리시오 테라퓨틱스, 인크. 돌연변이 kras 서열 및 지질을 포함하는 화합물 및 이의 용도

Similar Documents

Publication Publication Date Title
JP7504464B2 (ja) 核酸ワクチン
JP7330590B2 (ja) 水痘帯状疱疹ウイルス(vzv)のための核酸ワクチン
JP2021519595A (ja) 新規rsv rna分子及びワクチン接種用組成物
JP2013532971A5 (cg-RX-API-DMAC7.html)
KR20180096591A (ko) 광범위 인플루엔자 바이러스 백신
JP2024045151A (ja) Cpgアンフィフィル及びその使用
JP2008529558A5 (cg-RX-API-DMAC7.html)
JP2015529678A5 (cg-RX-API-DMAC7.html)
JP2023532290A5 (cg-RX-API-DMAC7.html)
JP2010530362A5 (cg-RX-API-DMAC7.html)
WO2024140767A1 (zh) 用于预防或治疗hpv感染相关疾病的多核苷酸分子
JP2022507373A5 (cg-RX-API-DMAC7.html)
RU2229307C1 (ru) Композиция рекомбинантных белков, способ получения такой композиции, фармацевтический набор реагентов для иммунотерапии и профилактической вакцинации опухолевых заболеваний аногенитальной сферы, способ иммунотерапии и профилактической вакцинации на его основе
JP2024512722A5 (cg-RX-API-DMAC7.html)
JP2011504108A5 (cg-RX-API-DMAC7.html)
JP2022513438A5 (cg-RX-API-DMAC7.html)
TH2001004949A (th) Cpg แอมพิฟิลและการใช้สิ่งดังกล่าว
RU2823677C2 (ru) Cpg амфифилы и их применения
WO2025092908A1 (zh) 治疗HPV感染相关疾病的mRNA疫苗
CN118021957A (zh) 一种编码抗禽流感H7N9病毒抗体的mRNA及其制法和应用
HK40045177B (en) Cpg amphiphiles and uses thereof
HK40045177A (en) Cpg amphiphiles and uses thereof
HK40043266A (en) Cpg amphiphiles and uses thereof
Wagner et al. What is the future of targeted therapy in head and neck cancer?
JP2014503174A5 (cg-RX-API-DMAC7.html)